Progressive Supranuclear Palsy - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Progressive Supranuclear Palsy - Pipeline Review, H1 2016', provides an overview of the Progressive Supranuclear Palsy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Progressive Supranuclear Palsy , complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Progressive Supranuclear Palsy and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Progressive Supranuclear Palsy - The report reviews pipeline therapeutics for Progressive Supranuclear Palsy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Progressive Supranuclear Palsy therapeutics and enlists all their major and minor projects - The report assesses Progressive Supranuclear Palsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Progressive Supranuclear Palsy Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Progressive Supranuclear Palsy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Progressive Supranuclear Palsy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Progressive Supranuclear Palsy Overview 7 Therapeutics Development 8 Pipeline Products for Progressive Supranuclear Palsy - Overview 8 Progressive Supranuclear Palsy - Therapeutics under Development by Companies 9 Progressive Supranuclear Palsy - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Progressive Supranuclear Palsy - Products under Development by Companies 13 Progressive Supranuclear Palsy - Companies Involved in Therapeutics Development 14 AB Science SA 14 AbbVie Inc. 15 AlzProtect SAS 16 Cortice Biosciences, Inc. 17 Merck & Co., Inc. 18 Otsuka Holdings Co., Ltd. 19 Prana Biotechnology Limited 20 Sellas Inc. 21 TauRx Therapeutics Ltd. 22 Progressive Supranuclear Palsy - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 ABBV-8E12 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 ASN-561 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 AVP-786 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 AZP-2006 - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 BMS-986168 - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 DC-TAB - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 DPC-016 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 masitinib - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 MK-8719 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 PBT-434 - Drug Profile 55 Product Description 55 Mechanism Of Action 55 R&D Progress 55 Small Molecules for Progressive Supranuclear Palsy - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 TPI-287 - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 TRx-0237 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 zolpidem tartrate - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 Progressive Supranuclear Palsy - Dormant Projects 66 Progressive Supranuclear Palsy - Product Development Milestones 67 Featured News & Press Releases 67 Jul 17, 2015: C2N And Abbvie Announce FDA Orphan Drug Designation Of C2N-8E12 (ABBV-8E12) For The Treatment Of Progressive Supranuclear Palsy 67 Jul 07, 2014: Cortice Announces Enrollment of a Phase 1 Clinical Trial Evaluating TPI 287 in Rare Tauopathy Diseases 67 Dec 10, 2013: Potential Treatment for Parkinson's & Parkinson-Like Diseases with Zolpidem: Sellas Life Sciences Group Holds Global Development & Marketing Rights 68 Appendix 70 Methodology 70 Coverage 70 Secondary Research 70 Primary Research 70 Expert Panel Validation 70 Contact Us 70 Disclaimer 71
List of Tables
Number of Products under Development for Progressive Supranuclear Palsy, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Development, H1 2016 12 Products under Development by Companies, H1 2016 13 Progressive Supranuclear Palsy - Pipeline by AB Science SA, H1 2016 14 Progressive Supranuclear Palsy - Pipeline by AbbVie Inc., H1 2016 15 Progressive Supranuclear Palsy - Pipeline by AlzProtect SAS, H1 2016 16 Progressive Supranuclear Palsy - Pipeline by Cortice Biosciences, Inc., H1 2016 17 Progressive Supranuclear Palsy - Pipeline by Merck & Co., Inc., H1 2016 18 Progressive Supranuclear Palsy - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 19 Progressive Supranuclear Palsy - Pipeline by Prana Biotechnology Limited, H1 2016 20 Progressive Supranuclear Palsy - Pipeline by Sellas Inc., H1 2016 21 Progressive Supranuclear Palsy - Pipeline by TauRx Therapeutics Ltd., H1 2016 22 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Stage and Target, H1 2016 25 Number of Products by Stage and Mechanism of Action, H1 2016 27 Number of Products by Stage and Route of Administration, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 31 Progressive Supranuclear Palsy - Dormant Projects, H1 2016 66
List of Figures
Number of Products under Development for Progressive Supranuclear Palsy, H1 2016 8 Number of Products under Development by Companies, H1 2016 9 Comparative Analysis by Clinical Stage Development, H1 2016 11 Comparative Analysis by Early Stage Products, H1 2016 12 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Top 10 Targets, H1 2016 24 Number of Products by Stage and Top 10 Targets, H1 2016 24 Number of Products by Top 10 Mechanism of Actions, H1 2016 26 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 26 Number of Products by Routes of Administration, H1 2016 28 Number of Products by Stage and Routes of Administration, H1 2016 28 Number of Products by Molecule Types, H1 2016 30 Number of Products by Stage and Molecule Types, H1 2016 30
Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance drivRead More...
Global non halogenated flame retardants market size is anticipated to be valued at USD 2.54 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing safety materials demand owing to low heat & smoke emission properties in cRead More...
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is antRead More...
Global LCP (Liquid Crystal Polymer) industry is forecasted to reach USD 1.23 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing trend towards developing militarized components and connectors are likely to drive the demandRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.